nasdaq:atrc
|
35769
|
Apr 21st, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1164
|
Open
|
|
Apr 20th, 2024 10:58PM
|
Apr 20th, 2024 10:58PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 20th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1164
|
Open
|
|
Apr 19th, 2024 10:56PM
|
Apr 20th, 2024 04:36PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 19th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1164
|
Open
|
|
Apr 18th, 2024 11:02PM
|
Apr 18th, 2024 11:02PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 18th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1164
|
Open
|
|
Apr 17th, 2024 11:01PM
|
Apr 18th, 2024 05:56PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 17th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1161
|
Open
|
|
Apr 16th, 2024 10:46PM
|
Apr 17th, 2024 02:20PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 16th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1161
|
Open
|
|
Apr 15th, 2024 10:43PM
|
Apr 16th, 2024 10:36AM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 15th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1162
|
Open
|
|
Apr 14th, 2024 10:44PM
|
Apr 15th, 2024 04:17PM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 14th, 2024 12:00AM
|
AtriCure, Inc.
|
32K
|
1162
|
Open
|
|
Apr 13th, 2024 10:38PM
|
Apr 14th, 2024 10:36AM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 13th, 2024 12:00AM
|
AtriCure, Inc.
|
31K
|
1163
|
Open
|
|
Apr 12th, 2024 10:28PM
|
Apr 13th, 2024 11:04AM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:atrc
|
35769
|
Apr 12th, 2024 12:00AM
|
AtriCure, Inc.
|
31K
|
1163
|
Open
|
|
Apr 11th, 2024 10:32PM
|
Apr 12th, 2024 07:59AM
|
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients.
AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.
For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
|
Open
|
Medical Devices, Manufacturing, Atrial Fibrillation, and Maze IV Training
|
Open
|
7555 Innovation Way
|
Mason
|
Ohio
|
US
|
45040
|
|
AtriCure
|
Health Care
|
Health Care Equipment & Services
|